このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

僧帽弁逆流の重症度を評価するためのフェニレフリンの使用

2026年11月12日 更新者:Montefiore Medical Center

経食道心エコー検査中にフェニレフリンを使用して僧帽弁逆流の重症度を評価する

The study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography (TEE), whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. The expectation is to see changes in severity of Mitral Regurgitation (MR) grade with increasing afterload, which in turn can provide more accurate quantification of MR severity to assist in clinical decision making.

調査の概要

状態

終了しました

条件

介入・治療

詳細な説明

Routine echocardiography which is used to assess the severity of mitral regurgitation, sometimes underestimates the severity of mitral regurgitation, due to hemodynamic variations that occurs with normal physical activity and under the effect of sedation which is used to perform transesophageal echocardiography. By using phenylephrine during transesophageal echocardiography, the study intends to offset the hemodynamic variation that occurs with sedation and better assess the severity of mitral regurgitation, which would further assist in clinical decision-making regarding treatment. The goal of this study is to compare the severity of mitral regurgitation grade before and after the administration of phenylephrine during transesophageal echocardiography and to demonstrate a 25% increase in severity of mitral regurgitation grade compared to the baseline conditions, following the administration of phenylephrine.

研究の種類

介入

入学 (実際)

8

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • New York
      • New York、New York、アメリカ、10470
        • Montefiore Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients 18 years or older with MR on baseline echocardiographic evaluation who are scheduled to undergo TEE for further evaluation of mitral regurgitation.

Exclusion Criteria:

  • The following patients will be excluded from the study:

    1. Patients who are not clinically eligible for TEE.
    2. Patients with contraindications to esophageal intubation.
    3. Patients with hemodynamic instability.
    4. Patients with acute decompensated heart failure (HF).
    5. Patients with un-revascularized severe coronary artery disease (triple vessel or left main disease).
    6. Patients with ongoing unstable angina or ongoing myocardial infarction (MI)
    7. Patients with significant arrhythmias including atrial fibrillation.
    8. Patients with uncontrolled hypertension (BP ≥ 150/90 mmHg).
    9. Patients with preexisting bradycardia (HR < 50) and heart blocks.
    10. Patients with severe symptomatic peripheral vascular disease.
    11. Patients with severe pulmonary hypertension (estimated systolic pulmonary arterial pressure sPAP ≥ 60mm Hg).
    12. Patients who are at high risk for intracranial bleeding such as patients with previous strokes, transient ischemic attack (TIA) and vascular malformations.
    13. Additionally, patients with mean arterial blood pressure MAP > 100 mmHg during TEE and those with severe MR, effective regurgitant orifice area (ERO > 39cm2) on baseline TEE evaluation will not be given phenylephrine and excluded from the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phenylephrine Hydrochloride

Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.

A 20 mcg intravenous test dose of phenylephrine will be administered by the cardiologist performing the TEE. BP will be monitored after each bolus of phenylephrine. Subsequent phenylephrine injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.

Phenylephrine hydrochloride injection (10 mg/mL) was diluted to 100 mcg/mL (10 mg in 99 mL of 5% dextrose or 0.9% sodium chloride) for intravenous bolus administration. A 20 mcg test dose was administered by the cardiologist performing the TEE, followed by 50 mcg boluses every 10-15 minutes until mean arterial pressure (MAP) increased by ≥20 mmHg from baseline MAP, without exceeding a MAP of 100 mmHg. Blood pressure was monitored after each bolus.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol.

Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in Effective Regurgitant Orifice Area (ERO)
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area.

Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in 3D Vena Contracta Diameter
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter.

Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in Visual Mitral Regurgitation Grade
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade.

Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Mario Garcia, MD、Montefiore Medical Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年12月1日

一次修了 (実際)

2022年7月19日

研究の完了 (実際)

2022年7月19日

試験登録日

最初に提出

2020年7月23日

QC基準を満たした最初の提出物

2020年8月3日

最初の投稿 (実際)

2020年8月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2020-11414

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。